A 6-Week, Multicentre, Randomised, Double-Blind, Double-Dummy, Active-Controlled, Clinical Safety Study of Lumiracoxib and Rofecoxib in Osteoarthritis Patients

BMC Musculoskeletal Disorders - United Kingdom
doi 10.1186/1471-2474-9-118
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC